Abstract
On the basis of promising animal studies and following the translational path of immune cell therapy in oncology,1 the field of organ transplantation has begun preliminary investigations of infusing regulatory immune cells into graft recipients. These early trials aim to reduce patients' immunosuppressive drug burden and promote drug-free transplant tolerance. The ONE Study was established in 2011 as a multicentre collaborative effort (centres in France, Germany, Italy, the UK, and the USA) to compare the feasibility, safety, and efficacy of regulatory cell-based medicinal products (CBMPs) when combined with reduced immunosuppressive treatment in low-risk, living-donor kidney recipients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
